Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.73 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 9/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14085825 | 0.87 | HDAC1 (0.67) | HDAC1HDAC9GSTO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7930002 | 0.86 | GAA (0.60) | HDAC1HDAC9ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL21226526 | 0.86 | HDAC1 (0.66) | HDAC1HDAC9GSTO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7930531 | 0.86 | ABL1 (0.68) | HDAC1HDAC9GSTO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28643881 | 0.86 | HDAC1 (0.66) | HDAC1HDAC9GSTO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4420194 | 0.85 | HDAC1 (0.65) | HDAC1HDAC9GSTO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10811295 | 0.84 | GSTO1 (0.72) | HDAC1HDAC9GSTO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10925697 | 0.84 | GSTO1 (0.72) | HDAC1HDAC9GSTO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22753355 | 0.84 | HDAC1 (0.63) | HDAC1HDAC9GSTO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21484709 | 0.83 | ABL1 (0.69) | HDAC1HDAC9GSTO1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | HDAC1 137/4885HDAC9 302/4885GSTO1 661/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | HDAC1 4782/4885HDAC9 3498/4885GSTO1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.